Product Description
Fluphenazine is a medication that treats schizophrenia. It is also known as a first generation antipsychotic (FGA) or typical antipsychotic. Fluphenazine rebalances dopamine to improve thinking, mood, and behavior. (Sourced from: https://www.nami.org/About-Mental-Illness/Treatments/Mental-Health-Medications/Types-of-Medication/Fluphenazine-(Prolixin))
Mechanisms of Action: DR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intramuscular,Oral,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Bangladesh | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Czech | Dominican Republic | Egypt | France | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Lebanon | Lithuania | Malaysia | Malta | Mexico | Morocco | New Zealand | Pakistan | Peru | Philippines | Portugal | Russia | Serbia | Slovakia | Slovenia | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Turkey | Ukraine | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|